RxDoctor Payments Data

Daria Wawrzyniak

Women's Health · Saint Louis, MONPI 1356053425

Payments from drug & device makers

$630in general payments, 2019–2025

Across 17 payments — averaging $37.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$186
  • 180 Medical, Inc.$151
  • Teleflex LLC$144
  • Organon$56
  • AbbVie$33
  • Sumitomo Pharma America, Inc.$20
  • plus $39 from 2 others

What the payments were for

  • Food & beverage$630100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$630 in reported general payments places this provider in the 55th percentile of 208 women's health providers in Missouri.

See all women's health providers in Missouri

Medicare billing

Part B allowed, 2024
$39,350
Medicare patients
263
Services billed
676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron300$185,052
GemtesaVibegron68$42,204
Fesoterodine Fumarate ErFesoterodine Fumarate72$8,871
Trospium Chloride ErTrospium Chloride59$8,061
Estradiol103$7,490
Solifenacin Succinate121$4,617
Methenamine Hippurate53$3,704
Trospium Chloride38$3,075
Tolterodine Tartrate ErTolterodine Tartrate43$1,987
Oxybutynin Chloride ErOxybutynin Chloride82$1,874
YuvafemEstradiol13$1,747
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst32$348
Hydroxyzine Hcl13$348
Cephalexin21$187
Tamsulosin Hcl17$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$20$42,20468 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 208 women's health providers in Missouri.

Other women's health in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →